Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting patient impact. At the 2026 ASCO GU meeting, experts gathered to share the ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
After menopause, urinary tract infections (UTIs) can be more frequent, yet most Canadian women (82 per cent in a recent survey) don’t realise the two are associated. At the Sex, Gender and Women’s ...
AstraZeneca has received approval from the European Commission for the use of Imfinzi (durvalumab) in combination with FLOT chemotherapy as a perioperative treatment for adults with resectable ...
Implement intuitive focus management. Batman buddy for this. Political meddling in etymology. Concussion leads to surface a key observation! The alligator should take special training yet. Slight ...
NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...
Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.
NCCN now recognizes BCG-unresponsive papillary-only NMIBC as eligible for nogapendekin plus BCG, broadening access beyond the ...
Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...
The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results